ClinicalTrials.gov
public full text
Public Domain
The Effectiveness of ACB-IP 1.0 Convalescent Plasma in COVID-19 Infection
Pathogen-free, concentrated, pooled convalescent plasma has higher SARS-CoV2 antibody titers and neutralizing antibody activities, without requiring blood group compatibility that allows patient accessibility in a shorter time and has safe plasma characteristic.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19#1009144
- Convalescent Plasma for the Treatment of COVID-19#888372
- Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma#844594
- COVID-19 With Convalescent Plasma#908583
- Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions#903862
Record · ID 871069
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive